The pharmaceutical industry has made enormous strides in treating—and even curing—a wide range of diseases and conditions. A key driver behind this progress? Billions in funding fueling research and development (R&D) at the cutting edge.
The global R&D pipeline has surged over the past two decades. In 2001, just 5,995 drugs were in the pipeline. Today, that number has soared to 23,875.
Leading the pack is Pfizer, with 271 drugs in development, followed by Roche (261), Novartis (254), AstraZeneca (241), and Sanofi (233). Pharma giant Eli Lilly ranks seventh with 224 drugs.
Of the nearly 24,000 drugs in the pipeline, about half (12,704) remain in the preclinical stage, while 1,568 are projected to launch in 2025.
The biggest focus area is oncology, which accounts for 9,476 drugs—roughly 40% of the total pipeline. Neurological drugs follow at 3,868, while metabolic drugs, boosted by the weight-loss drug boom, total 3,314.
Surprisingly, despite being the leading cause of death in the U.S., cardiovascular drugs rank ninth, with just 1,207 drugs in development.
Meanwhile, rare diseases represent another major focus, with 7,721 drugs in progress. Companies like Novartis and Bristol Myers Squibb are leading this charge, dedicating more than half of their pipelines to rare disease treatments—132 drugs (52%) and 115 drugs (50.2%), respectively.
Continue at: https://www.visualcapitalist.com/sp/ranked-which-areas-receive-the-most-pharma-rd/
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
